摘要
炎症性肠病(inflammatory bowel disease,IBD)是一组特定的肠道疾病的统称,主要体现为慢性及复发性的肠道炎症。其全球发病率正在迅速上升,严重影响人们生活质量与生命健康,已成为当前的全球性健康问题。在过去的几十年里,大量研究表明IBD的发病率与肠道菌群失调有关。因此,以肠道益生菌为主的治疗策略成为一大热点,其中大肠杆菌Nissle 1917(Escherichia coli Nissle 1917,EcN)备受关注。本文聚焦肠道益生菌EcN在治疗IBD中的应用与机制,系统地综述了EcN的益生菌特性,概述EcN在临床实践中对IBD的治疗应用,同时从上皮屏障完整性调节、免疫调节、黏液屏障保护和肠道菌群稳态等方面阐述EcN治疗IBD的具体作用机制。此外,结合当前的研究现状,讨论了未来基于工程化EcN新疗法的发展前景,强调EcN在IBD治疗和预防中的适用性和可行性策略,并对该领域未来的研究方向进行了展望,为进一步深入研究EcN治疗IBD提供思路和参考。
Inflammatory bowel disease(IBD)is a general term of a group of specific intestinal diseases,mainly manifested as chronic and recurrent intestinal inflammation.The burden of IBD has been a global health concern since its incidence and prevalence are elevating rapidly,which has seriously affected people's life and health quality.Over the past decades,tremendous studies underlined the association between incidence of IBD with imbalance of intestinal flora.Therefore,the treatment strategy based on probiotics has become the focus,among of them Escherichia coli Nissle 1917(EcN)has received accumulative attentions.In the current work,we focused on the application and mechanisms of EcN in the treatment of IBD,systematically reviewed the probiotic properties of EcN and its application for treating IBD through regulating epithelial integrity,immune-modulation,mucus protection and gut microbiota homeostasis.Furthermore,the future perspectives on formulating novel therapies based on engineered EcN were discussed,highlighting the applicable and feasible strategies of EcN in IBD curing and prevention.Besides,the prospects for further research in this field were given,providing ideas and references for further in-depth research on the EcN treatment of IBD.
作者
陈彩萍
任昊
龙腾飞
何冰
鲁兆祥
孙坚
CHEN Cai-ping;REN Hao;LONG Teng-fei;HE Bing;LU Zhao-xiang;SUN Jian(Department of Veterinary Medicine,South China Agriculture University,Guangzhou,510000;National Risk Assessment Laboratory for Antimicrobial Resistance of Animal Original Bacteria,South China Agricultural University,Guangzhou 510000;Guangdong Laboratory for Lingnan Modern Agriculture,Guangzhou 510000)
出处
《生物技术通报》
CAS
CSCD
北大核心
2023年第6期109-118,共10页
Biotechnology Bulletin
基金
国家自然科学基金重点项目(31730097)
广东省普通高校创新团队项目(2019KCXTD001)
国家自然科学基金青年科学基金项目(32102720)。
作者简介
陈彩萍,女,硕士,研究方向:细菌耐药性,E-mail:2532129689@qq.com;通讯作者:孙坚,男,博士,教授,研究方向:细菌耐药性,E-mail:jiansun@scau.edu.cn。
